FDA Approves Device for Pancreas Care - Scorecard - MDSpire

FDA Approves Device for Pancreas Care

In the phase 3 PANOVA-3 trial, adding Tumor Treating Fields therapy to gemcitabine and nab-paclitaxel was associated with improved overall survival and delayed pain progression in adults with locally advanced pancreatic cancer.

  • By

  • Kathryn Wighton

  • February 12, 2026

  • 3 min

Share

Clinical Scorecard: FDA Approves Device for Pancreas Care

At a Glance

CategoryDetail
ConditionLocally Advanced Pancreatic Cancer
Key MechanismsTumor Treating Fields disrupt cancer cell division and survival.
Target PopulationAdult patients with locally advanced pancreatic cancer.
Care SettingOutpatient and home-based care.

Key Highlights

  • Optune Pax approved for use with gemcitabine and nab-paclitaxel.
  • Median overall survival increased to 16 months with Optune Pax vs 14 months without.
  • One-year survival rates were 68% with Optune Pax vs 60% control.
  • Device-related skin adverse events occurred in 76% of treated patients.
  • First new FDA-approved treatment for locally advanced pancreatic cancer in nearly 30 years.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of locally advanced pancreatic cancer should be confirmed through imaging and biopsy.

Management

  • Optune Pax should be used in conjunction with gemcitabine and nab-paclitaxel.

Monitoring & Follow-up

  • Monitor for device-related skin adverse events and overall patient well-being.

Risks

  • Device-related skin adverse events are common but generally mild (grade 1 or 2).

Patient & Prescribing Data

571 patients enrolled in the PANOVA-3 trial.

Optune Pax improves overall survival and extends time to pain progression without increasing systemic toxicity.

Clinical Best Practices

  • Train patients on device placement and operation prior to use.
  • Integrate Optune Pax into daily life for enhanced patient compliance.

Related Resources & Content

Original Source(s)

FDA Approves Device for Pancreas Care

  • by Kathryn Wighton

  • February 12, 2026

Related Content

FDA Approves Treg Cell Therapy

A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.

Acute Kidney Injury Therapies Reviewed

Several interventions show early promise in high-risk patients, yet the field still awaits its first proven targeted therapy.

Deprivation Tied to Lower HNC-Specific QOL

The differences were present before patients began any treatment, suggesting quality-of-life gaps may be established before therapy begins.